CD274 and head and neck squamous cell carcinoma: Based on the observed efficacy and safety results, pembrolizumab and chemotherapy are now first-line treatment for patients with recurrent or metastatic HNSCC, whereas pembrolizumab monotherapy is the first-line treatment for patients with relapsed or metastatic PD-L1-positive HNSCC [55].